[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc purchased 1,200,000 ordinary shares of £0.01 each for cancellation under the second tranche of its share buyback programme announced 31 July 2025. Purchases took place on 11 August 2025 on the London Stock Exchange with a highest price of 357.0000p, lowest price of 352.2000p and a volume-weighted average price of 354.2107p. After settlement, registered share capital is 8,978,535,788 ordinary shares, with 3,880,205 held as treasury, leaving 8,974,655,583 ordinary shares with voting rights. A full trade breakdown is published via the provided RNS link and on the company's investor website; the announcement states it does not constitute an offer.

Positive

• Executed buyback tranche: Purchase and cancellation of 1,200,000 ordinary shares under the second tranche of the programme.
• Clear disclosure: Provided VWAP (354.2107p), high/low prices, updated registered capital and voting shares, plus a full trade breakdown link.

Negative

• None.

Insights

Financial Analyst

TL;DR: Small buyback reduces shares outstanding by 1.2M; immaterial versus the 8.98B share base.

The Company executed a tranche of its previously announced buyback, cancelling 1,200,000 shares at a VWAP of 354.2107p. The announcement supplies updated registered capital and voting share figures, allowing precise calculation of the reduced share count. Relative to a registered capital base of 8,978,535,788 shares, the tranche is very small and unlikely to meaningfully affect per-share metrics or valuation in isolation.

Corporate Governance Expert

TL;DR: Disclosure follows Market Abuse Regulation requirements and provides an individual trade breakdown and contact details.

The filing cites Article 5(1)(b) of Regulation (EU) No 596/2014 as applied in the UK and provides an RNS link to a full breakdown of individual trades plus publication on the company website. Contact details for investor and media enquiries are included, and the announcement explicitly says it does not constitute an offer. The filing reflects standard, transparent buyback disclosure practices.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	12 August 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

12 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,200,000 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	11 August 2025	11 August 2025	11 August 2025
Number of Shares purchased:	1,200,000	-	-
Highest price paid per Share (p):	357.0000	-	-
Lowest price paid per Share (p):	352.2000	-	-
Volume weighted average price paid per Share (p):	354.2107	-	-

Following the settlement of the above, the Company's registered share capital is 8,978,535,788 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,974,655,583 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/8800U_1-2025-8-11.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: August 12, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many shares did Haleon (HLN) purchase and cancel?

Haleon purchased and cancelled 1,200,000 ordinary shares of £0.01 each.

When and on which venue were the shares bought?

Purchases were made on 11 August 2025 on the London Stock Exchange (no trades reported on CBOE venues).

What were the price statistics for the buyback tranche?

The highest price paid was 357.0000p, the lowest 352.2000p, and the VWAP was 354.2107p.

What are the updated shares outstanding and voting shares?

Registered share capital is 8,978,535,788 shares, 3,880,205 are treasury shares, leaving 8,974,655,583 ordinary shares with voting rights.

Where can I find the full breakdown of individual trades?

A full trade breakdown is available at the RNS link provided in the announcement: http://www.rns-pdf.londonstockexchange.com/rns/8800U_1-2025-8-11.pdf and on www.haleon.com/investors.

Does this announcement constitute an offer for securities?

No. The announcement explicitly states it does not constitute, or form part of, an offer or solicitation of an offer for securities in any jurisdiction.